Will Pierre Fabre and Array Have Best-In-Class MEK/BRAF Inhibitor?

Jun 06 2018

Updated results from the COLUMBUS trial in BRAF-mutant advanced melanoma presented at ASCO revealed stellar overall survival data for the combination of encorafenib and binimetinib. Rivals Novartis and Roche will have noted that approval in the US is expected before the end of June.

Gears — Pierre Fabre and Array melanoma combo looks a good fit • Source: Shutterstock

Pierre Fabre Group and partner Array Biopharma Inc. are hoping for approvals on both sides of the Atlantic in the near future for their encorafenib and binimetinib combination treatment for melanoma, boosted by more positive data that have just been presented at the American Society of Clinical Oncology annual meeting in Chicago.

The companies announced updated results from the Phase III COLUMBUS trial in BRAF-mutant advanced melanoma which showed median overall survival...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

‘Attenuated’ Survival Benefit In Bemarituzumab Trial Delays Filing Plans

Sep 04 2025

• By Alaric DeArment

Amgen and Zai Lab said the final analysis of the FORTITUDE-101 trial showed a decreased magnitude of OS benefit in first-line gastric cancer.

Xoma On Its Royalty Model And Cleaning Up ‘Zombie’ Companies

Sep 04 2025

• By Manas Mishra and Andrew McConaghie

Seizing an opportunity to buy out struggling 'zombie' biotechs, Xoma is helping to return investor cash and pick up potential bargain assets for itself. Its CEO and chief investment officer explained their approach to Scrip.

Genmab/AbbVie’s Epkinly Could Get Competitive Edge With Outpatient Option

Sep 03 2025

• By Alaric DeArment

Phase II data showed it is feasible to give the CD20xCD3-targeting bispecific in the outpatient setting of DLBCL, while its current label calls for hospitalization.

BeOne Preps For Sonrotoclax MCL Filing, With Sights Set On AbbVie/Roche’s Territory

Aug 29 2025

• By Alaric DeArment

The biotech announced positive topline Phase I/II results for the BCL2 inhibitor in late-line mantle cell lymphoma, with Phase III studies underway in chronic lymphocytic leukemia.

AL-S Pharma’s AP-101 Shows Efficacy In ALS Clinical Trial

Sep 04 2025

• By Jessica Merrill

The Phase II study tested AP-101 safety and tolerability as the primary endpoint but showed “clinically meaningful” efficacy in exploratory endpoints.